AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05922475 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein
Description: Post-exercise protein group consumed protein immediately after exercise sessions.~Pre-sleep protein group consumed protein 30 minutes before sleep.
Study NCT05922475 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Resistance exercise training only group did not consume supplemental protein.
Study NCT02335736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropins releasing hormone antagonist
Study NCT02116959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Study NCT02116959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT02116959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Study NCT02116959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Study NCT00801580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin liposomal
Description: * Cyclophosphamide~* Mesna~* Methotrexate~* Doxorubicin liposomal~* Vincristine~* Dexamethasone~* Rituximab~* Cytarabine
Study NCT03024658 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: positive end expiratory pressure (PEEP)
Description: Positive end expiratory pressure was applied using anesthesia machine at the time of induction in the patients undergoing laparoscopic bariatric surgery
Study NCT04099550 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RT-CGM
Description: The group was monitored blood glucose initial 1-week with a RT-CGM.
Study NCT04099550 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SMBG
Description: The group was monitored self-monitoring blood glucose (SMBG) at least 2 times a day for initial 1-week.
Study NCT00283023 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oligodendrocyte progenitor cell culture/craniotomy
Description: Oligodendrocyte progenitor cell culture protocol of Rajavithi Hospital will be apply
Study NCT02739945 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cubital tunnel release
Description: The ulnar nerve is decompressed proximally at the intramuscular septum, decompressed more distally through the cubital tunnel and then exposed between the two heads of the flexor carpi ulnaris muscle. Care is taken to ensure that any point that might compress the ulnar nerve either proximally or distally is evaluated.
Study NCT01642459 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Same direction cannulation
Description: The puncture direction of the arterial needle is same as the blood flow in every hemodialysis session.
Study NCT01642459 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Opposite direction cannulation
Description: The puncture direction of the arterial needle is opposite to the blood flow in every hemodialysis session.
Study NCT02798744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: 25mg once daily to be taken orally for the duration of the study (24 weeks)
Study NCT01989988 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LMGB
Study NCT01989988 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LRYGB
Study NCT01989988 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SADJB
Study NCT03542955 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ActiPatch
Description: A Pulsed Shortwave Therapy Device
Study NCT03542955 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Etoricoxib 60 mg
Description: nonsteroidal anti-inflammatory drug used as standard therapy
Study NCT02650479 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Exenatide
Description: 6 hour IV infusion (double infusion of 0.1250 mcg/kg/hour for 30 min followed by infusion rate (1X) of 0.0625 mcg/kg/hour for 5.5 hours).
Study NCT02650479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: 6 hour IV infusion (double infusion of 0.1250 mcg/kg/hour for 30 min followed by infusion rate (1X) of 0.0625 mcg/kg/hour for 5.5 hours).
Study NCT02650479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 6 hour IV infusion.
Study NCT02650479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: 400 mg oral dose moxifloxacin within 1 min of start of infusion of exenatide
Study NCT02650479 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Palonosetron
Description: 0.25 mg administered IV within 30 minutes prior to initiating the infusion of exenatide
Study NCT02650479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: 0.25 mg administered IV within 30 minutes prior to initiating the infusion of exenatide
Study NCT02778659 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: The placebo will be administrated orally at 22:00 in the evening before a sleep recording and an early wake-up at 01:00 for cognitive and motor assessment.
Study NCT02330315 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Description: Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes.
Study NCT02330315 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS)
Description: Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes.
Study NCT02330315 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial ultrasound (TUS)
Description: Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
Study NCT02330315 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial ultrasound (TUS)
Description: Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
Study NCT01775852 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ACT-IM
Description: 1 hour discussion about migraine management (IM) and 5 hours of group therapy based on Acceptance and Commitment Therapy (ACT). IM covers symptoms and triggers for worsening of migraine symptoms, how to use migraine medications, medication overuse headache, etc. The ACT intervention includes: 1) Behavioral Change Training and; 2) Mindfulness and Acceptance Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations.
Study NCT01090830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat, carboplatin, paclitaxel and bevacizumab
Description: Induction therapy will include 6 cycles of 5-days of medication administration followed by a 16 day rest period. Belinostat will be given once a day for 5 days total. Three dose levels will be evaluated (600mg/kg, 800 mg/kg, and 1000 mg/kg). In addition, participants will receive fixed doses of intravenous carboplatin (AUC 6), Paclitaxel (200 mg/m2), and bevacizumab (15 mg/kg) once on day 3 of each cycle. Serial disease status evaluations will be done throughout the study.~In the absence of significant toxicity or disease progression, participants may continue with a maintenance regimen of bevacizumab and Belinostat for an additional 6 cycles. The dose of Belinostat received during maintenance will be that tolerated in the initial 6 cycles.
Study NCT03173638 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intravitreal injection of MSV
Description: A unique intravitreal injection of MSV in acute fase of NAION
Study NCT00556400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lo-Ovral Oral Contraceptive Pills
Study NCT00556400 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - sugar pill
Study NCT02552056 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAMH training
Description: Training of PHC workers included in the study for 5 days to screen children and adolescents for CAMH conditions, based in the mhGAP curriculum for non-specialist health providers.
Study NCT03376230 — intervention group
Intervention type: OTHER
Intervention: Collect of blood, urines, and intestinal biopsies
Study NCT02422771 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FIFA 11+ warm-up
Description: A sequence of 15 exercises performed before soccer practices and games. The exercises include strength, agility, balance and motor control components and take about 15-20 minutes to perform. The intervention replaces any previous warm-up the athletes may have done.
Study NCT01133886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Patients will receive decitabine as a 20mg/m2 one hour intravenous infusion once daily on days 1 to 5 of a 4 week cycle.
Study NCT03449550 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Respiratory Polygraphy (HRP)
Description: Randomizing to start with home respiratory polygraphy
Study NCT03449550 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Polysomnography (PSG)
Description: Randomizing to start with Standard Polysomnography (PSG)
Study NCT03449550 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Respiratory Polygraphy (HRP)
Description: Randomizing for therapeutic decision taken with home respiratory polygraphy (HRP)
Study NCT03449550 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Polysomnography (PSG)
Description: Randomizing for therapeutic decision taken with Standard Polysomnography (PSG)
Study NCT02967796 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Proteochoc
Study NCT02798744 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Daily energy restriction diet to be followed for the duration of the study (24 weeks)
Study NCT03091426 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle
Study NCT05067712 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Surgical Exposure Technique
Description: * A mucoperiosteal palatal flap is elevated off the bone from the premolar to the midline~* The bone covering the crown aspect of the canine is removed until the largest diameter of the crown is exposed~* Follicular tissue is removed from the exposed crown area~* The flap is repositioned back and sutured~* The area over the exposed canine crown is excised leaving a window with the crown uncovered.~* If the tooth is deeply embedded in the bone, a dressing is placed over the uncovered crown and kept in place with sutures.~* The extraction of the primary canine (if present) is made before or in connection with the surgical exposure.~* Ten to fifteen days later the dressing and sutures are removed and the tooth is left to erupt autonomously.~* When the canine has spontaneously erupted above the palatal mucosa an attachment is bonded to the crown and the canine is moved into alignment in the dental arch above the mucosa with orthodontic appliances.
Study NCT02798744 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Daily energy restriction diet to be followed for the duration of the study (24 weeks)
Study NCT05067712 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closed Surgical Exposure Technique
Description: * A mucoperiosteal palatal flap is elevated off the bone from the premolar to the midline~* The bone covering the crown aspect of the canine is removed until the largest diameter of the crown is exposed.~* Follicular tissue is removed from the exposed crown area.~* An attachment with a chain is bonded to the exposed canine crown.~* The flap is repositioned back and sutured to cover the exposed crown leaving the chain through the palatal mucosa free in the oral cavity~* The extraction of the primary canine (if present) made before or in connection with the surgical exposure~* Ten to fifteen days later the sutures are removed.~* Within days, traction is applied to the canine with orthodontic appliances by means of the chain, and the canine is pulled through the palatal mucosa out to the oral cavity and into alignment in the dental arch.
Study NCT02798744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily for the duration of the study (24 weeks)
Study NCT02798744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo once daily for the duration of the study (24 weeks)
Study NCT03818906 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Molar extraction - Control Group
Description: The extra-oral measurements will be made for further comparison and assessment of swelling (48 hours and 7 days). Exodontia will be done in a conventional way and the evolution of the pain will be evaluated through the visual analog scale during the next 7 days.
Study NCT04325685 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Oropharyngeal decontamination with saline will be performing three time a day every 8 hours during mechanical ventilation
Study NCT04325685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiseptic Solution
Description: Oropharyngeal decontamination with antiseptic solution will be performing three time a day every 8 hours during mechanical ventilation
Study NCT04325685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacteriophage
Description: Oropharyngeal decontamination with bacteriophage will be performing three time a day every 8 hours during mechanical ventilation
Study NCT06522178 — intervention group
Intervention type: OTHER
Intervention: Patient' ages
Description: Patients were divided into two groups according to their ages.
Study NCT03932162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin-Like Growth Factor 1
Description: Growth factor protein
Study NCT03818906 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: aPDT + Molar Extraction - Test Group 1
Description: The extra-oral measurements will be made for further comparison and assessment of swelling (48 hours and 7 days). Exodontia will be done in a conventional way and the evolution of the pain will be evaluated through the visual analog scale during the next 7 days.immediately after extraction, the fresh sockets will receive in their internal portion a local application of aPDT.
Study NCT03818906 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infrared + Molar Extraction - Test Group 2
Description: The extra-oral measurements will be made for further comparison and assessment of swelling (48 hours and 7 days). Exodontia will be done in a conventional way and the evolution of the pain will be evaluated through the visual analog scale during the next 7 days.immediately after extraction, the fresh sockets will receive local application of infrared in vestibular external portion
Study NCT03818906 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: aPDT + Infrared + Molar Extraction - Test Group 3
Description: The extra-oral measurements will be made for further comparison and assessment of swelling (48 hours and 7 days). Exodontia will be done in a conventional way and the evolution of the pain will be evaluated through the visual analog scale during the next 7 days.immediately after extraction, the fresh sockets will receive in their internal portion a local application of aPDT and after that will receive local application of infrared in vestibular external portion.
Study NCT00325130 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Quadrivalent Human Papillomavirus (HPV) vaccine
Description: Quadrivalent HPV vaccine was provided by the SPONSOR in single-dose vials containing a volume of 0.75 mL. The vaccine was administered as a~0.5-mL intramuscular dose at Day 1, Month 2, and Month 6.
Study NCT00325130 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Menactra™ (Concomitant)
Description: A single administration of 0.5 mL intramuscular injection in a limb opposite that of quadrivalent HPV injection at Day 1
Study NCT00325130 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Adacel™ (Concomitant)
Description: a single administration of 0.5 mL intramuscular injection administered in a limb opposite that of quadrivalent HPV injection at Day 1
Study NCT00325130 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Menactra™ (Non-concomitant)
Description: A single administration of 0.5 mL intramuscular injection in a limb opposite that of quadrivalent HPV injection at Month 1
Study NCT03932162 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Insulin-Lie Growth Factor 1
Description: No Insulin-Like Growth Factor 1 will be given.
Study NCT02362867 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Balanced Knee System
Description: A multi-compartmental total knee replacement providing a system of components for primary posterior cruciate ligament substituting procedures. The system consists of femoral, tibial, and patellar components that allow the surgeon to select the most appropriate component combination to meet specific patient needs.
Study NCT02901197 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education and Reminder Posters
Description: See arm description
Study NCT02901197 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Policy Change
Description: See arm description
Study NCT03041064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 50/100
Description: SPF
Study NCT03041064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 100/50
Description: SPF
Study NCT02245555 — intervention group
Intervention type: DRUG
Intervention: Tamsulosin
Study NCT03953859 — intervention group
Intervention type: GENETIC
Intervention: double strand break
Description: an induction of a double strand break will be made in the embryos generated for this research and the repair mechanism observed
Study NCT04749784 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Dose Arterin Cholesterol
Description: 240mg active ingredient daily
Study NCT04749784 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Dose Arterin Cholesterol
Description: 120mg active ingredient daily
Study NCT04749784 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study NCT00220038 — intervention group
Intervention type: BEHAVIORAL
Intervention: smell tests
Description: subjects are instructed to sniff two vials, one containing the solvent, the other a dilution of the odorant. They are asked to scan the vial with the stronger odor.
Study NCT04761536 — intervention group
Intervention type: OTHER
Intervention: Rectal cancer case centralization
Description: In November 2016, the decision to centralize rectal cancer patients to only one surgical unit was taken, with only two surgeons performing the procedures. Furthermore, a close collaboration with local Gastroenterology Units and General Practiotioners was started in order to increase colorectal cancer case referral to our unit. At the same time, we decided to promote the use of laparoscopy and to implement ERAS protocol in our colorectal surgery practice.
Study NCT05729997 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Listening to live classical music
Description: The group of musicians perform music in the hemodialysis room while patients receive treatment.
Study NCT00912600 — intervention group
Intervention type: OTHER
Intervention: Intensive Care Unit admission
Description: Intensive Care Unit admission
Study NCT01721291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SALBUTAMOL
Description: In the LUNG DEPOSITION STUDY; SALBUTAMOL INHALED VIA RESEARCH NEBULISER at 3 PARTICLES SIZES OF 1.5 MICRONS, 3 MICRONS AND 6 MICRONS WILL BE GIVEN AT SLOW INHLATION AND AGAIN AT FAST INHALTION;DOSAGE- 30 MICROGRAMS, ONE SINGLE INHALATION ONLY. IN ADDITION, SALBUTAMOL AT 200 MICROGRAMS INHALED VIA A STANDARD METERED DOSE INHALER WILL ALSO BE GIVEN AS A SINGLE INHALATION.~In the LUNG PHYSIOLOGY STUDY; SALBUTAMOL INHALED VIA RESEARCH NEBULISER at 3 PARTICLES SIZES OF 1.5 MICRONS, 3 MICRONS AND 6 MICRONS WILL BE GIVEN AT TWO DOSAGES OF 30 MICROGRAMS AND AGAIN AT 15 MICROGRAMS, ONE SINGLE INHALATION ONLY. IN ADDITION, SALBUTAMOL AT 200 MICROGRAMS INHALED VIA A STANDARD METERED DOSE INHALER WILL ALSO BE GIVEN AS A SINGLE INHALATION. ALL INHALATIONS WIL BE AT SLOW INHALTION IN THIS PART OF THE STUDY.
Study NCT01721291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SALBUTAMOL
Description: In the LUNG DEPOSITION STUDY; SALBUTAMOL INHALED VIA RESEARCH NEBULISER at 3 PARTICLES SIZES OF 1.5 MICRONS, 3 MICRONS AND 6 MICRONS WILL BE GIVEN AT SLOW INHLATION AND AGAIN AT FAST INHALTION;DOSAGE- 30 MICROGRAMS, ONE SINGLE INHALATION ONLY. IN ADDITION, SALBUTAMOL AT 200 MICROGRAMS INHALED VIA A STANDARD METERED DOSE INHALER WILL ALSO BE GIVEN AS A SINGLE INHALATION.~In the LUNG PHYSIOLOGY STUDY; SALBUTAMOL INHALED VIA RESEARCH NEBULISER at 3 PARTICLES SIZES OF 1.5 MICRONS, 3 MICRONS AND 6 MICRONS WILL BE GIVEN AT TWO DOSAGES OF 30 MICROGRAMS AND AGAIN AT 15 MICROGRAMS, ONE SINGLE INHALATION ONLY. IN ADDITION, SALBUTAMOL AT 200 MICROGRAMS INHALED VIA A STANDARD METERED DOSE INHALER WILL ALSO BE GIVEN AS A SINGLE INHALATION. ALL INHALATIONS WIL BE AT SLOW INHALTION IN THIS PART OF THE STUDY.